Encapsulated embryonic stem cell-derived pancreatic progenitor cells for treatment of diabetes
CyT49 is comprised of a human embryonic stem cell (hESC) line differentiated into pancreatic epithelium (PE) and loaded into bilaminar Theracyte™ encapsulation devices. The devices were implanted into a diabetic model in mice and into nude rats.
The cells matured and produced insulin in a glucose-sensing manner only in mice. The diabetic mice were salvaged by the implantation.
Read More
Product Information for
Encapsulated embryonic stem cell-derived pancreatic progenitor cells for treatment of diabetes
Links related to the product - may include a range of information sources (e.g., press releases, websites, patents) related to the specific cell therapy application.
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access